• Corpus ID: 76322784

Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery

@inproceedings{Srihirun2016CurrentAN,
  title={Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery},
  author={Sirada Srihirun and สิรดา ศรีหิรัญ and Nathawut Sibmooh and ณัฐวุธ สิบหมู่},
  year={2016}
}
Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery Sirada Srihirun, Nathawut Sibmooh Sirada Srihirun, Nathawut Sibmooh 1 Department of Pharmacology, Faculty of Dentistry, Mahidol University Email: Sirada.srh@mahidol.ac.th 2 Department of Pharmacology, Faculty of Science, Mahidol University Email: Nathawut.sib@mahidol.ac.th Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery 

Figures and Tables from this paper

References

SHOWING 1-10 OF 52 REFERENCES

Thienopyridines and other ADP-receptor antagonists.

Whether individualized antiplatelet treatment incorporating different P2Y12 receptor inhibitors improves patients' clinical outcomes warrants further investigation.

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.

Preclinical and clinical data on cangrelor and AZD6140 are summarized and the potential of these compounds as novel antiplatelet therapies are discussed.

The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

Cangrelor influences the ability of the active metabolites of clopidogrel or prasugrel to inhibit platelet function irreversibly, and careful consideration should be given to the timing of administration of an oral P2Y12 antagonist following cangrelor infusion.

Cangrelor: a review on its mechanism of action and clinical development

An overview of the current status of knowledge on cangrelor is provided, focusing on its pharmacologic properties, clinical development and potential future applications.

New P2Y12 Inhibitors

P2Y12 stabilizes the platelet aggregates and amplifies the secretion of platelet dense granules stimulated by secretion-inducing agonists, making it an attractive molecular target for therapeutic intervention and the target of efficacious antithrombotic agents.

Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation

The data indicate that P2Y12 is targeted by ticagrelor via a mechanism that is non‐competitive with ADP, suggesting the existence of an independent receptor‐binding site for CPTPs.

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.

Clinical studies in patients with cardiovascular disease confirmed the potent antiplatelet effect of prasugrel compared with clopidogrel and aided in dose selection for the recently completed phase 3 trial of patients with acute coronary syndrome undergoing percutaneous coronary intervention.

New Directions in Antiplatelet Therapy

The objective of the present manuscript is to provide an overview on the most recent advances of currently approved antiplatelet agents in the setting of ACS and PCI, as well as on emerging agents that are in clinical development.

Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy.

P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents.

  • M. Cattaneo
  • Biology, Chemistry
    European heart journal
  • 2006
P2Y12 mediates the potentiation of platelet secretion induced by strong agonists and the stabilization of thrombin-induced platelet aggregates, making it an attractive molecular target for therapeutic intervention.
...